Compare Franklin Resources, Inc. (BEN) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs GSK plc — how do they compare? Franklin Resources, Inc. trades at $33.37 (market cap $16.95B), while GSK plc trades at $50.62 (market cap $102.60B). The key difference: GSK plc is far larger — about 6.1× Franklin Resources, Inc.'s market cap, and Franklin Resources, Inc. pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BEN | GSK | |
|---|---|---|
Market Cap | $16.95B | $102.60B |
Sector | Financials | Health |
52-Week High | $35.77 | $61.18 |
52-Week Low | $21.18 | $38.22 |
Enterprise Value | $29.90B | $123.04B |
Dividend Yield | 3.96% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.52, down 0.74% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $0.72, beating estimates, and achieved record AUM of $1.80 trillion as of July 31, 2026, driven by strong inflows and diversification efforts. Valuation ratios include a P/E of 22.69 and P/S of 1.85, while profitability metrics show a net income margin of 8.72%.
The outlook is positive with earnings beats and AUM growth, but risks include weaker ROE of 1.34% and net cash outflows. Analyst consensus price target is $36.50, suggesting potential upside, supported by a 'Buy' rating from 22% of analysts. Investors should monitor margin expansion and competitive pressures in the asset management sector.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
